These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29528251)

  • 41. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials.
    Moran GJ; De Anda C; Das AF; Green S; Mehra P; Prokocimer P
    Infect Dis Ther; 2018 Dec; 7(4):509-522. PubMed ID: 30242736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.
    Chahine EB; Sucher AJ; Knutsen SD
    Consult Pharm; 2015 Jul; 30(7):386-94. PubMed ID: 26173190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A closer inspection of tedizolid.
    Drekonja DM
    Lancet Infect Dis; 2015 Apr; 15(4):374. PubMed ID: 25809886
    [No Abstract]   [Full Text] [Related]  

  • 44. A closer inspection of tedizolid.
    Taylor J
    Lancet Infect Dis; 2015 Apr; 15(4):374. PubMed ID: 25809887
    [No Abstract]   [Full Text] [Related]  

  • 45. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
    Lodise TP; Fang E; Minassian SL; Prokocimer PG
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
    Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
    Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
    Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A closer inspection of tedizolid - authors' reply.
    Prokocimer P; Corey GR; Das AF; Moran GJ
    Lancet Infect Dis; 2015 Apr; 15(4):375. PubMed ID: 25809888
    [No Abstract]   [Full Text] [Related]  

  • 50. New antibiotics for skin and skin-structure infections.
    Tacconelli E; Kern WV
    Lancet Infect Dis; 2014 Aug; 14(8):659-661. PubMed ID: 24909500
    [No Abstract]   [Full Text] [Related]  

  • 51. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.
    Ferrández O; Urbina O; Grau S
    Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.
    Hall RG; Michaels HN
    Infect Drug Resist; 2015; 8():75-82. PubMed ID: 25960671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system.
    Gatti M; Fusaroli M; Raschi E; Moretti U; Poluzzi E; De Ponti F
    Expert Opin Drug Saf; 2021 Nov; 20(11):1421-1431. PubMed ID: 34280062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy.
    Bassetti M; Castaldo N; Carnelutti A; Peghin M; Giacobbe DR
    Core Evid; 2019; 14():31-40. PubMed ID: 31308835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis.
    Lan SH; Lin WT; Chang SP; Lu LC; Chao CM; Lai CC; Wang JH
    Antibiotics (Basel); 2019 Sep; 8(3):. PubMed ID: 31487837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
    Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
    Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.
    Nathwani D; Corey R; Das AF; Sandison T; De Anda C; Prokocimer P
    Clin Infect Dis; 2017 Jan; 64(2):214-217. PubMed ID: 28003218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.